An observational study in Chronic Pain, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by University Hospital, Clermont-Ferrand · Observational
Pickering G, Voute M, Sorel M, Pereira B, Riant T. Sex and Age Differences in Ketamine Efficacy and Safety in Chronic Pain Alleviation. J Clin Med. 2025 Jun 16…PubMed 40566014 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Chronic Pain by University Hospital, Clermont-Ferrand — 5 open to participants now, 6 under way, none of them phase 3. Chronic Pain · University Hospital, Clermont-Ferrand.
Among the 22 studies in Chronic Pain by University Hospital, Clermont-Ferrand, this one is the 6th largest by enrollment of the 13 observational ones that give a count, is one of 3 that started in 2016, is one of 13 observational ones, and was the 9th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →5 of the 22 studies in Chronic Pain by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 50–70
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–53 · Women only
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 585 is above the median of 120 across 755 observational studies indexed under Chronic Pain.
Median enrollment 55 across the 9 interventional studies, 501 across the 13 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
1 of the studies in Chronic Pain by University Hospital, Clermont-Ferrand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07786688University Hospital, Clermont-FerrandPrevalence of Childhood Maltreatment Among Women With Dysmenorrhea. | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Chronic Pain by University Hospital, Clermont-Ferrand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.
This is an observational, longitudinal and multicenter study about use of ketamine. Benefits are assessed with pain intensity, anxiety, depression, quality of life and global impression of change. Risks are also assessed with adverse event collection.
Patients with chronic pain
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Neuropathic pain patient taking ketamine
Other: ketamine
The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.
Descriptive analysis of benefit
Benefits (pain release after ketamine use) will be assessed by the Pain by the Numerical Pain Rating Scale (NPRS): the scale ranges from 0 no pain to 10 maximal tolerable pain, and risks will be assessed by collecting the ketamine adverse events reported by the patient and by the physician.
Time frame: At baseline
Descriptive analysis of risk (by collecting adverse event) of ketamine use.
Biological statements will be collected during the usual care of patients, if possible (ASAT, ALAT, total bilirubin, conjugate bilirubin, free bilirubin, gamma glutamyl transferase, alkaline phosphatase,…)
Time frame: At baseline
Neuropathic Pain in 4 questions (DN4),
The Neuropathic pain in 4 questions (DN4) at baseline only. DN4 is a clinical tool for the diagnosis of neuropathic pain. This questionnaire has four questions divided into 10 items related to the interview (ie, symptoms) and to the sensory examination (ie, signs). The investigator asks and examines the patient and notes a response "no" or "yes" for each item: "yes" is scored as "1" and "no" is scored as "0". The sum of scores gives the total score of the patient (/10). DN4 is considered as positive if the patient obtains a score of 4/10.
Time frame: At baseline
Patient Global Impression of Change, the characteristics of pain (PGIC)
The Patient Global Impression of Change is a scale of global perception of change ("Deterioration" or "Improvement") realized at each telephone call except for baseline. This scale is graduated from 1 = very strongly improved to 7 = very strongly aggravated
Time frame: At baseline
Emotional status by Hospital Anxiety and Depression scale (HAD)
The HAD scale is a self-administered questionnaire in 14 items completed by the patient. It is used to determine the levels of anxiety and depression. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. Global score ranges from 0 to 42.
Time frame: At baseline
Quality of life (Short Form 12 items Short Form survey)
assessed by a quality of life questionnaire (Short Form 12 items Short Form survey (SF12)
Time frame: At baseline
Ran from Jul 2016 to primary completion in Sep 2017, 14 months.
Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's 14 months is below that.
Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2018 → Sep 2017, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Pickering G, Voute M, Sorel M, Pereira B, Riant T. Sex and Age Differences in Ketamine Efficacy and Safety in Chronic Pain Alleviation. J Clin Med. 2025 Jun 16…PubMed 40566014 ↗
Pickering G, Voute M, Sorel M, Pereira B, Riant T. Sex and Age Differences in Ketamine Efficacy and Safety in Chronic Pain Alleviation. J Clin Med. 2025 Jun 16…PubMed 40566014 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →